{
    "clinical_study": {
        "@rank": "60417", 
        "arm_group": [
            {
                "arm_group_label": "Low-fat dairy", 
                "arm_group_type": "Experimental", 
                "description": "3 servings/d of low-fat dairy"
            }, 
            {
                "arm_group_label": "Sugar-sweetened beverages", 
                "arm_group_type": "Placebo Comparator", 
                "description": "3 servings/d of sugar-sweetened foods"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this trial is to evaluate the effects of dairy product consumption on insulin\n      sensitivity and pancreatic \u03b2-cell function in men and women at risk for the development of\n      type 2 diabetes mellitus (T2DM) who habitually consume beverages high in sugar (non-diet\n      sodas and fruit juice cocktails)."
        }, 
        "brief_title": "Clinical Trial to Assess the Effects of Dairy on Insulin Sensitivity and \u03b2-Cell Function", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Insulin Resistance"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  subject is male or female, 18-74 yrs of age, inclusive\n\n          -  subject reports habitual consumption of \u22652 servings/d of high-sugar beverages (e.g.,\n             non-diet soda, fruit juice cocktails)\n\n          -  subject has waist circumference \u226533.0 inches for women and \u226536.0 inches for men\n\n          -  subject is at risk for development of type 2 diabetes mellitus (T2DM), based on 1 or\n             more of the following: fasting glucose 100-125 mg/dL; glycosylated hemoglobin\n             5.7-6.4%, or \u226520% risk of developing diabetes in the next 7.5 yrs based on the San\n             Antonio Heart Study prediction equation\n\n          -  subject has a score of 7-10 on the Vein Access Scale at screening\n\n          -  subject is normally active and judged to be in good health on the basis of medical\n             history, physical examination and routine lab tests\n\n          -  if female, subject is willing to schedule treatment visits during the follicular\n             phase of the menstrual cycle, defined as days 1-14, where day 1 is 1st day of menses\n\n          -  subject has a menstrual cycle duration ranging in length form 24-36 d (if\n             premenopausal)\n\n          -  subject is willing to maintain a stable body weight and follow his/her habitual diet\n             and exercise pattern, except for inclusion of study product, throughout the trial\n\n          -  subject is willing to maintain his or her habitual intake of coffee, tea, and\n             alcoholic beverages throughout the trial\n\n          -  subject agrees to limit intake of non-study related dairy products to \u22641 serving per\n             day during each treatment period\n\n          -  subject is ambulatory and willing to refrain from vigorous physical activity and\n             consumption of alcoholic beverages 24 h prior to each test day\n\n          -  subject has no plans to change smoking habits during the study period\n\n          -  subject is willing to abstain from tobacco use 1 h prior to and during visits on LMTT\n             test days\n\n          -  subject has no health conditions that would prevent him/her from fulfilling the study\n             requirements as judged by the Investigator on the basis of medical history and\n             routine lab test results\n\n        Exclusion Criteria:\n\n          -  subject has abnormal lab test results of clinical importance, including, but not\n             limited to, TG \u2265400 mg/dL, fasting creatinine \u22651.5 mg/dL, alanine aminotransferase or\n             aspartate aminotransferase \u22651.5 times the upper limit of normal at screening\n\n          -  subject has a body mass index \u226545.0 kg/m2\n\n          -  subject has fasting blood glucose \u2265126 mg/dL at screening or known diabetes mellitus\n             (type 1 or T2DM)\n\n          -  subject has a habitual intake of \u22654 servings/d of dairy food and beverages\n\n          -  subject has known allergy or sensitivity to study product or any ingredients of study\n             product.  Subjects with lactose intolerance will be allowed to use products such as\n             Lactaid dietary supplements\n\n          -  subject has a history of coronary heart disease, congestive heart failure, or serious\n             ventricular dysrhythmias (ventricular tachycardia or fibrillation)\n\n          -  subject has a change in body weight of >4.5 kg within 4 weeks of screening\n\n          -  subject uses medications known to influence carbohydrate metabolism\n\n          -  subject has recent use of antibiotics\n\n          -  subject has an active infection\n\n          -  subject has unstable use of anti-hypertensive medications, thyroid hormone\n             replacement, or lipid-altering drugs within 4 weeks of screening\n\n          -  subject has unstable use of lipid-altering foods or dietary supplements within 4\n             weeks of screening\n\n          -  subject uses niacin at doses >200 mg/d within 4 weeks of screening\n\n          -  subject has history of extreme dietary habits, e.g., Atkins, high protein\n\n          -  subject has a history or presence of clinically important endocrine, cardiac, renal,\n             hepatic, pulmonary, biliary, pancreatic, gastrointestinal, or neurologic disorders\n             that could interfere with interpretation of study results\n\n          -  subject has history of dysphagia, swallowing disorders, or intestinal motility\n             disorders\n\n          -  subject has history of cancer\n\n          -  subject has uncontrolled hypertension at screening (systolic blood pressure \u2265160 mm\n             Hg or diastolic blood pressure \u2265100 mm Hg)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "74 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "44", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01936935", 
            "org_study_id": "PRV-1222"
        }, 
        "intervention": [
            {
                "arm_group_label": "Low-fat dairy", 
                "description": "2 servings/d of 2% non-flavored, unsweetened milk + 1 serving/d sweetened low-fat yogurt", 
                "intervention_name": "Low-fat dairy", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Sugar-sweetened beverages", 
                "description": "2 servings/d of non-diet soda + 1 serving/d of non-dairy pudding", 
                "intervention_name": "Sugar-sweetened beverages", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Insulin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Insulin sensitivity", 
        "lastchanged_date": "September 3, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Addison", 
                    "country": "United States", 
                    "state": "Illinois", 
                    "zip": "60101"
                }, 
                "name": "Provident Clinical Research (now Biofortis)"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Controlled, Crossover Trial to Assess the Effects of Dairy Intake on Insulin Sensitivity and \u03b2-Cell Function in Men and Women at Risk for Diabetes Who Are Habitual Consumers of High Sugar Beverages", 
        "other_outcome": [
            {
                "description": "Mean circulating glucose level will be measured over 24 h in the continuous glucose monitoring (CGM) subset of subjects", 
                "measure": "Mean circulating glucose level", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Mean daytime glucose values (6 am to 8 pm) measured in the CGM subset of subjects", 
                "measure": "Mean daytime glucose values", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Mean evening/nighttime glucose values (8 pm to 6 am) measured in the CGM subset of subjects", 
                "measure": "Mean evening/nighttime glucose values", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Mean peak postprandial glucose values during CGM after the lunch and dinner meals", 
                "measure": "Mean peak postprandial glucose", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }
        ], 
        "overall_official": {
            "affiliation": "Biofortis Clinical Research", 
            "last_name": "Kevin C Maki, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "MISI calculated from glucose and insulin data obtained during a liquid meal tolerance test (LMTT).  MISI = 10,000 divided by the square root of the quantity of fasting glucose x fasting insulin x mean post-load glucose from samples collected at 30, 60, 90 and 120 min after the start of the liquid meal x mean post-load insulin from samples collected at 30, 60, 90 and 120 min after the start of the liquid meal", 
            "measure": "Matsuda Insulin Sensitivity Index (MISI)", 
            "safety_issue": "No", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01936935"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Measured using a non-stretch anthropometric tape", 
                "measure": "Waist circumference", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Standardized vital signs measurements will include resting blood pressure and pulse measured using an automated blood pressure measurement device.", 
                "measure": "Blood pressure", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "During the LMTT subjects consume a liquid meal load (two-8 oz servings of Ensure\u00ae, Ross Products Division, Abbott Laboratories, Columbus, Ohio), and blood samples will be obtained at t = -10, 30, 60, 90, and 120 min \u00b1 5 min where t = 0 min is the start of meal consumption.  Serum insulin and plasma glucose concentrations will be measured in fasting (-10 min) and 2 hr (120 min) samples.", 
                "measure": "Fasting and 2-hr LMTT insulin and glucose concentrations", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "HOMA-IR = the quantity of fasting glucose in mg/dL x fasting insulin in microunits/mL divided by 405", 
                "measure": "Homeostasis model assessment of insulin resistance (HOMA-IR)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "HOMA%B = 360 x fasting insulin in microunits/mL divided by fasting glucose in mg/dL minus 63", 
                "measure": "Homeostasis model assessment of beta-cell function (HOMA%B)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Glucose total AUC 0-120 min will be calculated using the trapezoidal rule on glucose concentrations in blood samples collected at -10, 30, 60, 90, and 120 min where 0 min is the start of the liquid meal consumption in the LMTT.", 
                "measure": "Glucose total area under the curve (AUC) from 0-120 min", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Insulin total AUC 0-120 min will be calculated using the trapezoidal rule on insulin concentrations in blood samples collected at -10, 30, 60, 90, and 120 min where 0 min is the start of the liquid meal consumption in the LMTT.", 
                "measure": "Insulin total AUC 0-120 min", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Change in insulin from baseline to 30 min of the LMTT will be divided by the change in glucose from baseline to 30 min of the LMTT", 
                "measure": "30 min \u0394 insulin/\u0394 glucose", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "AUC for insulin divided by the AUC for glucose", 
                "measure": "AUC insulin/AUC glucose", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Disposition index = MISI x the quantity of AUC for insulin divided by the AUC for glucose", 
                "measure": "Disposition Index", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Fasting plasma total cholesterol (total-C)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Calculated as LDL-C = total-C minus HDL-C minus the quantity of triglycerides (TG) divided by 5", 
                "measure": "Fasting plasma low-density lipoprotein cholesterol (LDL-C)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Fasting plasma high-density lipoprotein cholesterol (HDL-C)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Calculated as total-C concentration divided by HDL-C concentration", 
                "measure": "Fasting plasma total-C/HDL-C", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Calculated as non-HDL-C = total-C minus HDL-C", 
                "measure": "Fasting plasma non-HDL-C", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Fasting plasma TG", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Serum 25-hydroxy vitamin D [25(OH)D]", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Plasma high-sensitivity C-reactive protein (hs-CRP)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }
        ], 
        "source": "Provident Clinical Research", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "BioFortis", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Dairy Research Institute", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Provident Clinical Research", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}